Jun 2026 (Q2 FY26) — Aug 5, 2026
USANA Health Sciences, Inc. Q2 FY26 — Core Nutritional Strength Amidst Venture Challenges
Read the full callUSANA Health Sciences (USNA) earnings
- Jul 2026
- Jun 2026 (Q2 FY26)
- Jan 2026
USANA Health Sciences earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 223 | −5.3% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | -9.0 | −16.1 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | -21.4 | −321.5% YoY | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. |
Price
$14.89 −4.18% · −$0.65
Performance −28.7% 1Y
1Y: $20.89 on 17 Oct 2025 → $14.89. High $23.24 (28 Jul 2026), low $12.86 (17 Aug 2026).
- Previous close
- $15.54
- 52-week range
- $12.86 – $23.24
- One year
- −28.00%
Overview
- Symbol
- USNA
- Sector
- Consumer Staples
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
USANA Health Sciences earnings calls (USNA)
Financials
What the filings say
Net profit, year on year: −321% (quarter to jul 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 200 | 214 | 250 | 236 | 214 | 226 | 250 | 223 |
| Operating profit | 16 | 8 | 16 | 17 | 1 | 4 | 14 | -20 |
| Operating margin | 7.8% | 3.8% | 6.3% | 7.1% | 0.6% | 1.7% | 5.5% | −9.0% |
| Other income | 3 | 2 | 1 | 2 | 1 | 0 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 19 | 10 | 17 | 19 | 2 | 4 | 15 | -19 |
| Tax rate | 43.0% | 57.0% | 44.5% | 44.5% | 471.4% | 138.2% | 55.0% | −47.9% |
| Net profit | 11 | 4 | 9 | 10 | -7 | -2 | 8 | -21 |
| EPS ($ per share) | 0.56 | — | 0.49 | 0.52 | -0.36 | — | 0.41 | -1.16 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 330 | 306 | 383 | 345 | 392 | 445 | 479 | 466 |
| Total liabilities | 163 | 165 | 199 | 183 | 162 | 136 | 162 | 157 |
| Fixed assets | 92 | 95 | 100 | 102 | 98 | 100 | 95 | 94 |
| Total assets | 554 | 517 | 641 | 578 | 597 | 633 | 748 | 743 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 152 | 127 | 160 | 121 | 104 | 71 | 61 | 22 |
| Cash from investing | -69 | 47 | -34 | -14 | -12 | -12 | -213 | -10 |
| Cash from financing | -105 | -152 | -59 | -181 | -30 | -14 | 10 | -41 |
| Net cash flow | -33 | 20 | 78 | -72 | 48 | 42 | -149 | -23 |
| Capital expenditure | -11 | -17 | -15 | -13 | -10 | -14 | -10 | -14 |
| Free cash flow | 141 | 110 | 145 | 108 | 94 | 56 | 51 | 9 |
Insider filings
119 filings between Oct 23, 2025 and Jul 25, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$990.6K
17 sales by 9 insiders
Compensation
not trading decisions- 59
- Option exercise — converted options into shares
- 43
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Jones Paul A. | — | $232.0K | Jun 8, 2026 |
| Foukas Joshua | — | $170.4K | May 7, 2026 |
| Neidig Brent | — | $147.8K | Jun 16, 2026 |
| Benedict Peter | — | $144.3K | Mar 3, 2026 |
| IIEKKING G DOUG | — | $100.5K | May 27, 2026 |
| Fleming John Turman | — | $78.6K | Jun 1, 2026 |
| FULLER GILBERT A | — | $60.4K | May 22, 2026 |
| Winssinger Frederic J | — | $38.4K | Nov 10, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 25, 2026 | Armstrong Kathryn Michelle CHIEF SCIENTIFIC OFFICER | Tax withheld | 518 | $11.0K |
| Jul 25, 2026 | Armstrong Kathryn Michelle CHIEF SCIENTIFIC OFFICER | Option exercise | 1,166 | — |
| Jul 25, 2026 | Benedict Peter CHIEF INFORMATION OFFICER | Tax withheld | 176 | $3.8K |
| Jul 25, 2026 | Benedict Peter CHIEF INFORMATION OFFICER | Option exercise | 598 | — |
| Jul 23, 2026 | FULLER GILBERT A Director | Option exercise | 1,632 | — |
| Jul 23, 2026 | Pelosi Peggie Director | Tax withheld | 935 | $19.6K |
| Jul 23, 2026 | Ding Xia Director | Option exercise | 1,632 | — |
| Jul 23, 2026 | Ding Xia Director | Tax withheld | 604 | $12.6K |
| Jul 23, 2026 | Nixon J Scott Director | Option exercise | 1,632 | — |
| Jul 23, 2026 | Winssinger Frederic J Director | Option exercise | 1,632 | — |
| Jul 23, 2026 | Fleming John Turman Director | Option exercise | 1,632 | — |
| Jul 23, 2026 | WOOD TIMOTHY E Director | Tax withheld | 408 | $8.5K |
| Jul 23, 2026 | Pelosi Peggie Director | Option exercise | 1,632 | — |
| Jul 23, 2026 | WOOD TIMOTHY E Director | Option exercise | 1,632 | — |
| Jun 16, 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Sale | 5,002 | $97.3K |
| Jun 15, 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Sale | 909 | $18.2K |
| Jun 12, 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Sale | 1,602 | $32.3K |
| Jun 8, 2026 | Jones Paul A. CHIEF PEOPLE OFFICER | Sale | 5,561 | $102.9K |
| Jun 1, 2026 | Fleming John Turman Director | Sale | 2,450 | $43.9K |
| May 28, 2026 | Jones Paul A. CHIEF PEOPLE OFFICER | Sale | 6,813 | $129.1K |
| May 27, 2026 | IIEKKING G DOUG CHIEF FINANCIAL OFFICER | Sale | 5,360 | $100.5K |
| May 22, 2026 | FULLER GILBERT A Director | Sale | 1,057 | $19.7K |
| May 7, 2026 | Foukas Joshua CHIEF LEGAL OFFICER | Sale | 3,791 | $75.1K |
| Apr 23, 2026 | FULLER GILBERT A Director | Option exercise | 1,057 | — |
| Apr 23, 2026 | Winssinger Frederic J Director | Option exercise | 1,057 | — |
| Apr 23, 2026 | WOOD TIMOTHY E Director | Tax withheld | 264 | $5.1K |
| Apr 23, 2026 | WOOD TIMOTHY E Director | Option exercise | 1,057 | — |
| Apr 23, 2026 | Pelosi Peggie Director | Option exercise | 1,057 | — |
| Apr 23, 2026 | Pelosi Peggie Director | Tax withheld | 668 | $12.9K |
| Apr 23, 2026 | Fleming John Turman Director | Option exercise | 1,057 | — |
| Apr 23, 2026 | Nixon J Scott Director | Option exercise | 1,057 | — |
| Apr 23, 2026 | Ding Xia Director | Tax withheld | 391 | $7.5K |
| Apr 23, 2026 | Ding Xia Director | Option exercise | 1,057 | — |
| Mar 20, 2026 | FULLER GILBERT A Director | Sale | 1,058 | $18.0K |
| Mar 3, 2026 | Benedict Peter CHIEF INFORMATION OFFICER | Sale | 4,553 | $88.3K |
| Feb 27, 2026 | Armstrong Kathryn Michelle CHIEF SCIENTIFIC OFFICER | Option exercise | 4,190 | — |
| Feb 27, 2026 | Benedict Peter CHIEF INFORMATION OFFICER | Tax withheld | 1,174 | $25.3K |
| Feb 27, 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Tax withheld | 2,993 | $64.4K |
| Feb 27, 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Option exercise | 6,747 | — |
| Feb 27, 2026 | Foukas Joshua CHIEF LEGAL OFFICER | Tax withheld | 2,786 | $60.0K |
| Feb 27, 2026 | Foukas Joshua CHIEF LEGAL OFFICER | Option exercise | 6,577 | — |
| Feb 27, 2026 | Noot Walter CHIEF OPERATING OFFICER | Tax withheld | 3,144 | $67.7K |
| Feb 27, 2026 | Noot Walter CHIEF OPERATING OFFICER | Option exercise | 7,422 | — |
| Feb 27, 2026 | Jones Paul A. CHIEF PEOPLE OFFICER | Tax withheld | 1,349 | $29.0K |
| Feb 27, 2026 | Jones Paul A. CHIEF PEOPLE OFFICER | Option exercise | 4,596 | — |
| Feb 27, 2026 | Benedict Peter CHIEF INFORMATION OFFICER | Option exercise | 3,906 | — |
| Feb 27, 2026 | Guest Kevin CEO & EXEC. CHAIRMAN OF BOARD | Tax withheld | 3,328 | $71.6K |
| Feb 27, 2026 | Guest Kevin CEO & EXEC. CHAIRMAN OF BOARD | Option exercise | 7,856 | — |
| Feb 27, 2026 | IIEKKING G DOUG CHIEF FINANCIAL OFFICER | Tax withheld | 5,031 | $108.3K |
| Feb 27, 2026 | IIEKKING G DOUG CHIEF FINANCIAL OFFICER | Option exercise | 7,469 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for USANA HEALTH SCIENCES INC
Free account. Everything above stays public.
Write why you follow USANA HEALTH SCIENCES INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading